Moreover, we found that different individual SGLT2 inhibitors had similar associations with the risk of composite anemia outcomes, including empagliflozin (HR, 0.80; 95% CI, 0.72-0.89), dapagliflozin (HR, 0.80; 95% CI, 0.72-0.90) and canagliflozin (HR, 0.76; 95% CI, 0.64-0.90) (eTable 9 in Supplement 1). This evidence concerns the gene SLC5A2 and anemia (phenotype).